Abstract:Objective:To evaluate the results of neuroblastoma (NB) based upon risk-adapted therapy.Methods:From September 2002 to December 2018, clinical data were reviewed for 483 newly diagnosed NB patients aged ≤18 years based on risk-adapted therapy. They were stratified into low, intermediate and high-risk groups by age, stage, histological category and MYCN status. There were 290 males and 193 females with a median diagnostic age of 3.5 years (7 days to 18 years). The stages were 1 (n=19) , 2 (n=25) , 3 (n=95) , 4 (n=334) and 4S (n=10). Surgery alone or surgery plus low intensive chemotherapy for low-risk group (n=46, 9.5%) ; Surgery plus moderate intensive chemotherapy with or without radiotherapy for intermediate-risk group (n=102, 21.1%) ; For high-risk group (n=335, 69.4%) , before 2013, the treatment strategies included 8 cycles of alternating chemotherapy of cyclophosphamide (CTX) + vincristine (VCR) + pirarubicin (THP) and cisplatin (DDP) + etoposide (VP16) , surgery, with or without autologous hematopoietic stem cell transplantation (ASCT) , radiotherapy, with or without biotherapy and isotretinoin maintenance therapy for 1 year; after 2013, 8 cycles of alternating chemotherapy of CTX + VCR + THP and VP16 + ifosfamide + DDP protocol, surgery, radiotherapy, with or without biological therapy and oral maintenance chemotherapy drugs for 1 year. Recurrent patients received salvage therapy.Results:MYCN amplification was 22.4 % (72/322) in all groups and 33.8%(72/213) in high-risk group. ASCT was performed for only 15 cases. During a median follow-up period of 38(2.5-208) months, 3-year event-free survival (EFS) and overall survival (OS) were (86.5±5.1) % and 100% for low-risk group ; (79.1±4.3)% and (89.2±3.3) % for intermediate-risk group ; (30.6±2.7)% and (60.3±2.9)% for high-risk group respectively. Univariate survival analysis of 335 high-risk patients indicated that stage 4 and chemotherapy alone were poor prognostic factors for EFS/OS. Multivariate survival analysis showed that stage 4 and chemotherapy alone were independent adverse prognostic factors for EFS in high-risk NB patients while stage 4, chemotherapy alone and primary abdominal lesions were independent adverse prognostic factors for OS in high-risk NB patients. The 3-year EFS for MYCN positive high-risk patients was (27.4±6.3) % and for MYCN negative high-risk patients (36.7±4.4) % and the inter-group difference was statistically significant ( P=0.049). The 3-year EFS for MYCN positive high-risk patients with stage 4 was (18.7±6.7) % and for MYCN positive high-risk patients with stage 3/4S was (49.4±13.1) % and the inter-group difference was statistically significant ( P=0.009). In high-risk complete/partial remission patients without ASCT, 3-year EFS of oral isotretinoin maintenance therapy was (28.0±5.1)% while 3- year EFS of oral chemotherapy maintenance therapy was (42.1±5.1)% and the inter-group difference was statistically significant ( P=0.019). In high-risk patients, 3-year EFS for the therapeutic model of chemotherapy + surgery + radiotherapy was 37.1% , 19.0% for chemotherapy + surgery and 7.7% for chemotherapy alone. And the inter-group differences were statistically significant ( P<0.001). The 3-year EFS in high-risk group was (21.5±4.1 ) % before 2013 and (34.9±3.6) % after 2013. And the inter-group difference was statistically significant ( P=0.004) ; 3- year OS in high-risk group was (47.7±4.9)% before 2013 and (66.7±3.6) % after 2013. And the inter-group difference was statistically significant ( P<0.001). Conclusions:NB may be stratified into low, intermediate and high-risk groups based upon age, stage, histological category and MYCN status. For risk-adapted therapy, low and intermediate groups have better survival. High-risk patients have poor survival and new therapy should be explored. Salvage therapy for recurrent NB offers a survival benefit.

Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy

Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification

Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

[Long-Term Follow-Ups of Comprehensive Therapies for Stage 4 Neuroblastoma].

High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Outcome analysis of neuroblastoma based upon risk-adapted therapy: a report of 483 cases

Long term follow-up of children with neuroblastoma without chemotherapy and radiotherapy

[Therapeutic Experience of Childhood Stage III Neuroblastoma].

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma

Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

Pediatric high risk neuroblastoma with autologous stem cell transplant - 20 years of experience

Multivariate Analysis of Risk Factors for Patients with Stage 4 Neuroblastoma Who Were Older Than 18 Months at Diagnosis: a Report from a Single Institute in Shanghai, China

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group

Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review

Bone Marrow Relapse in Stage 4 Neuroblastoma of Children in Shanghai.

[Comprehensive Protocol for Diagnosis and Treatment of Childhood Neuroblastoma--results of 45 Cases].